S
Zodix
Study
Academic Library
Search
Shelves
Open access
Sign in
Search or jump to…
⌘K
Yufeng Ding · Study
Home
/
Author
Yufeng Ding
1 works
· latest 2021
· 1 institutions
cluster: provisional
ORCID 0000-0002-0321-7139
Follow
Suggest an ORCID correction
h-index
1
i10
1
Citations
55
Works here
1
21
Most cited in this library
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
2021 · 55 citations
Works
1 shown
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Frontiers in Oncology
·
2021
·
4 authors
·
Open access
55
citations